Hvsen Biotechnology Co., Ltd.
SZSE:300871.SZ
14.16 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,200.328 | 1,019.759 | 1,022.901 | 996.217 | 777.459 | 427.217 | 421.874 | 399.716 | 257.783 |
| Cost of Revenue
| 1,004.268 | 809.956 | 797.537 | 725.496 | 489.589 | 263.549 | 238.147 | 197.016 | 122.002 |
| Gross Profit
| 196.06 | 209.803 | 225.363 | 270.721 | 287.87 | 163.668 | 183.727 | 202.7 | 135.781 |
| Gross Profit Ratio
| 0.163 | 0.206 | 0.22 | 0.272 | 0.37 | 0.383 | 0.436 | 0.507 | 0.527 |
| Reseach & Development Expenses
| 55.797 | 27.659 | 40.138 | 46.888 | 28.382 | 21.109 | 20.356 | 17.952 | 12.793 |
| General & Administrative Expenses
| 11.67 | 10.544 | 11.092 | 17.328 | 13.706 | -25.167 | -24.465 | -19.967 | 15.386 |
| Selling & Marketing Expenses
| 27.967 | 23.917 | 48.428 | 47.154 | 52.556 | 38.821 | 46.742 | 57.86 | 49.242 |
| SG&A
| 39.637 | 155.402 | 59.52 | 64.482 | 66.262 | 13.653 | 22.277 | 37.893 | 64.628 |
| Other Expenses
| 129.711 | 11.659 | -2.447 | -0.195 | -0.485 | 3.065 | 2.434 | 0.148 | 3.671 |
| Operating Expenses
| 225.145 | 194.72 | 146.038 | 134.531 | 109.849 | 80.362 | 88.245 | 97.219 | 80.059 |
| Operating Income
| -29.085 | 15.083 | 59.157 | 151.028 | 176.517 | 78.555 | 81.49 | 103.38 | 54.517 |
| Operating Income Ratio
| -0.024 | 0.015 | 0.058 | 0.152 | 0.227 | 0.184 | 0.193 | 0.259 | 0.211 |
| Total Other Income Expenses Net
| 0.112 | -2.641 | -2.447 | -0.195 | -0.485 | 0.046 | 0.178 | 0.344 | 3.246 |
| Income Before Tax
| -28.973 | 12.442 | 56.71 | 150.832 | 176.032 | 78.602 | 81.668 | 103.724 | 58.188 |
| Income Before Tax Ratio
| -0.024 | 0.012 | 0.055 | 0.151 | 0.226 | 0.184 | 0.194 | 0.259 | 0.226 |
| Income Tax Expense
| -9.2 | -4.339 | 4.003 | 17.967 | 25.876 | 9.836 | 10.266 | 15.314 | 8.79 |
| Net Income
| -20.156 | 16.781 | 52.706 | 132.866 | 150.156 | 68.766 | 71.402 | 88.424 | 49.423 |
| Net Income Ratio
| -0.017 | 0.016 | 0.052 | 0.133 | 0.193 | 0.161 | 0.169 | 0.221 | 0.192 |
| EPS
| -0.12 | 0.1 | 0.32 | 0.8 | 0.91 | 0.41 | 0.59 | 0.74 | 0.41 |
| EPS Diluted
| -0.12 | 0.1 | 0.32 | 0.8 | 0.91 | 0.41 | 0.59 | 0.74 | 0.41 |
| EBITDA
| 126.977 | 161.378 | 138.227 | 182.646 | 197.735 | 93.442 | 96.095 | 114.37 | 65.919 |
| EBITDA Ratio
| 0.106 | 0.158 | 0.135 | 0.183 | 0.254 | 0.219 | 0.228 | 0.286 | 0.256 |